Melioidosis in Tropical ICUs: Recognition, Management, and Outcomes in Critical Care Settings

Dr Neeraj Manikath , claude.ai

Abstract

Background: Melioidosis, caused by Burkholderia pseudomallei, represents one of the most challenging infectious diseases encountered in tropical intensive care units (ICUs). Often misdiagnosed as tuberculosis or pneumonia, this condition carries significant morbidity and mortality, particularly when diagnosis and treatment are delayed.

Objectives: To provide critical care physicians with evidence-based guidance on the recognition, diagnosis, and management of melioidosis in ICU settings, with emphasis on practical clinical pearls and diagnostic challenges.

Methods: Comprehensive review of current literature, clinical guidelines, and expert recommendations for melioidosis management in critical care settings.

Results: Early recognition and appropriate antibiotic therapy are crucial for survival. Mortality rates range from 20-50% in ICU patients, with septic shock and multiple organ failure being common presentations. Diagnostic challenges include cross-reactivity with other gram-negative organisms and the fastidious nature of B. pseudomallei.

Conclusions: Heightened clinical suspicion, appropriate diagnostic testing, and prompt initiation of targeted therapy are essential for improving outcomes in critically ill patients with melioidosis.

Keywords: Melioidosis, Burkholderia pseudomallei, tropical medicine, critical care, sepsis, pneumonia

Introduction

Melioidosis, caused by the gram-negative bacterium Burkholderia pseudomallei, stands as one of the most formidable infectious challenges facing intensivists in tropical and subtropical regions. First described by Alfred Whitmore and C.S. Krishnaswami in 1911 in Myanmar, this condition has earned the sobriquet "the great mimicker" for its protean clinical manifestations that can resemble tuberculosis, pneumonia, or other systemic infections¹.

The global burden of melioidosis is substantial, with an estimated 165,000 cases annually and 89,000 deaths worldwide². Endemic regions include Southeast Asia, Northern Australia, parts of the Indian subcontinent, Southern China, and increasingly recognized areas in the Americas and Africa³. For critical care physicians practicing in these regions, melioidosis represents a diagnostic and therapeutic emergency where delays can prove fatal.

B. pseudomallei is a saprophytic organism that thrives in soil and water, particularly in tropical climates with distinct wet and dry seasons. Human infection typically occurs through percutaneous inoculation, inhalation, or ingestion of contaminated environmental sources⁴. The organism's remarkable adaptability, including its ability to survive within phagocytes and form biofilms, contributes to both acute severe disease and chronic, relapsing infections that can emerge years after initial exposure⁵.

Epidemiology and Risk Factors

Geographic Distribution

Melioidosis demonstrates a highly focal geographic distribution, with hyperendemic areas often existing alongside regions where the disease is virtually unknown. The highest incidence rates are reported from:

Northern Australia: Particularly the Northern Territory, with incidence rates up to 50 cases per 100,000 population during the wet season⁶
Northeast Thailand: The global epicenter, with incidence rates exceeding 21 per 100,000 in some provinces⁷
Malaysia and Singapore: Significant burden in both urban and rural settings⁸
Myanmar, Laos, Cambodia, and Vietnam: High endemicity with underreporting due to limited diagnostic capabilities⁹

High-Risk Populations

Critical care physicians should maintain heightened suspicion in patients with the following risk factors:

Diabetes mellitus (present in 50-80% of cases)¹⁰
Chronic kidney disease
Chronic lung disease
Immunosuppression (HIV, malignancy, corticosteroid use)
Excessive alcohol consumption
Advanced age (>45 years)
Occupational or recreational soil/water exposure¹¹

Seasonal Patterns

In endemic areas, melioidosis demonstrates distinct seasonal variation, with case numbers typically increasing during and immediately following the wet season. This pattern reflects increased environmental bacterial loads and enhanced aerosolization during heavy rainfall events¹².

Pathogenesis and Clinical Manifestations

Pathophysiologic Mechanisms

B. pseudomallei possesses remarkable virulence mechanisms that enable both acute fulminant disease and chronic latent infection:

Intracellular survival: The organism can survive and replicate within macrophages, epithelial cells, and other host cells¹³
Biofilm formation: Facilitates persistence and resistance to host immune responses¹⁴
Multi-nucleated giant cell formation: Characteristic histopathological finding¹⁵
Immune evasion: Multiple mechanisms to avoid host immune recognition¹⁶

Clinical Presentations in ICU Settings

Melioidosis patients requiring intensive care typically present with one of several distinct clinical syndromes:

1. Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

Prevalence: 60-80% of ICU cases¹⁷
Characteristics:
- Bilateral infiltrates common
- Upper lobe predilection (mimicking tuberculosis)
- Cavitation in 30-50% of cases
- Rapid progression to ARDS
- Parapneumonic effusions frequent

2. Septic Shock with Multi-organ Failure

Clinical features:
- Profound vasodilation
- Distributive shock pattern
- Acute kidney injury (70% of severe cases)¹⁸
- Coagulopathy and thrombocytopenia
- Encephalopathy

3. Disseminated Abscess Formation

Common sites:
- Liver and spleen (40-60% of bacteremic cases)¹⁹
- Lung
- Prostate (males)
- Skeletal muscle
- Central nervous system
Characteristics:
- Multiple, thin-walled abscesses
- Central necrosis with minimal surrounding inflammation
- May require prolonged drainage

4. Central Nervous System Involvement

Manifestations:
- Meningoencephalitis
- Cerebral abscesses
- Brainstem involvement
Mortality: Exceeds 50% even with appropriate therapy²⁰

Diagnostic Challenges and Laboratory Findings

The Great Mimicker: Differential Diagnosis

Melioidosis' clinical similarity to other serious infections creates significant diagnostic challenges:

Tuberculosis mimicry:

Upper lobe pneumonia
Cavitation
Chronic course in some cases
Similar demographic (diabetes, immunocompromised)

Community-acquired pneumonia:

Acute onset
Bilateral infiltrates
Systemic toxicity

Other considerations:

Tularemia
Glanders
Plague
Typhoid fever
Septic embolization from endocarditis

Laboratory Diagnosis

Conventional Culture Methods

Gold standard: Isolation of B. pseudomallei from clinical specimens
Growth characteristics:
- Oxidase positive
- Growth on MacConkey agar
- Characteristic "earth-like" odor
- Wrinkled colony morphology
Challenges:
- Slow growth (48-72 hours)
- Overgrowth by other organisms
- Safety concerns (BSL-3 pathogen)²¹

Selective Media

Ashdown's agar: Contains gentamicin and crystal violet to suppress other organisms²²
Francis medium: Alternative selective medium
Sensitivity: Improved recovery from mixed specimens

Rapid Diagnostic Methods

Latex agglutination: Rapid but limited sensitivity (60-70%)²³
Immunofluorescent assays: Higher sensitivity but requires expertise
PCR-based methods: Promising but not widely available²⁴
MALDI-TOF MS: Rapid species identification from pure cultures²⁵

Serology

Indirect hemagglutination assay (IHA): Most widely used
Interpretation:
- Single titer ≥1:160 suggestive in endemic areas
- Four-fold rise in convalescent sera diagnostic
Limitations:
- Cross-reactivity with other Burkholderia species
- Delayed antibody response in immunocompromised patients²⁶

Imaging Findings

Chest Radiography

Common patterns:
- Bilateral alveolar infiltrates (60%)
- Upper lobe consolidation (40%)
- Cavitation (30-50%)
- Pleural effusion (30%)²⁷

Computed Tomography

Enhanced sensitivity for detecting:
- Early cavitation
- Multiple lung abscesses
- Pleural thickening
- Extrapulmonary abscesses²⁸

Abdominal Imaging

Ultrasound/CT findings:
- Multiple hypoechoic lesions in liver/spleen
- "Honeycomb" appearance of abscesses
- Splenic infarcts
- Ascites in severe cases²⁹

Management in Critical Care Settings

Antibiotic Therapy

Successful treatment of severe melioidosis requires a two-phase approach:

Phase 1: Intensive Therapy (Initial 2-4 weeks)

First-line agents:

Ceftazidime: 2g IV every 8 hours (or 6g/day continuous infusion)³⁰
Meropenem: 1g IV every 8 hours³¹
Imipenem: 500mg IV every 6 hours³²

Comparative efficacy:

Meropenem may have slight survival advantage over ceftazidime³³
Imipenem associated with higher neurological toxicity
Continuous infusion ceftazidime may optimize pharmacodynamics³⁴

Adjunctive therapy:

Trimethoprim-sulfamethoxazole (TMP-SMX): 8mg/kg TMP component daily in divided doses
Evidence: May reduce relapse rates when added to beta-lactam therapy³⁵
Granulocyte colony-stimulating factor (G-CSF): Controversial, some benefit in severe cases³⁶

Phase 2: Eradication Therapy (3-6 months)

Standard regimen:

TMP-SMX: 8mg/kg TMP component daily
Alternative agents:
- Doxycycline: 100mg twice daily
- Amoxicillin-clavulanate: 625mg three times daily³⁷

Duration of Therapy

Uncomplicated cases: Minimum 12 weeks total Complicated cases: 20 weeks or longer Central nervous system involvement: 6 months minimum Relapse management: Retreat with full course³⁸

Supportive Care

Hemodynamic Support

Fluid resuscitation: Early aggressive fluid therapy
Vasopressors: Norepinephrine preferred agent
Inotropic support: May be required for myocardial depression³⁹

Respiratory Support

Mechanical ventilation: Often required for ARDS
ECMO: Case reports of successful salvage therapy⁴⁰
Prone positioning: Standard ARDS protocols apply

Renal Replacement Therapy

Indications: Standard criteria for AKI
Antibiotic dosing: Adjust for clearance during CRRT⁴¹

Surgical Management

Indications for drainage:

Large abscesses (>5cm)
Loculated collections
Persistent fever despite appropriate antibiotics
Complications (rupture, secondary infection)⁴²

Approaches:

Percutaneous drainage preferred when feasible
Surgical drainage for complex collections
Video-assisted thoracoscopic surgery (VATS) for pleural complications⁴³

Clinical Pearls and Diagnostic Hacks

🔍 Diagnostic Pearls

"MELIOID" Mnemonic:
- Multiple abscesses
- Endemic area exposure
- Liver/spleen involvement
- Immunocompromised/diabetes
- Oxidase positive gram-negative rod
- Increased during wet season
- Distributive shock pattern
The "Wet Season Rule": In endemic areas, any severe sepsis during or after the rainy season should prompt melioidosis consideration⁴⁴
"Sweet Spot" Sign: Prostatic abscesses in men with gram-negative bacteremia should raise suspicion⁴⁵
"Double Trouble": Concurrent bacterial infections are common; don't stop looking for other pathogens⁴⁶

🚨 Red Flag Indicators

Rapid cavitation: Pneumonia with cavitation developing within 48-72 hours
Multi-organ involvement: Simultaneous pulmonary and hepatosplenic disease
Treatment-resistant sepsis: Poor response to standard broad-spectrum antibiotics
"Honeycomb liver": Multiple small abscesses on imaging

🎯 Management Hacks

"Start High, Stay Long": Use maximum doses of beta-lactams and continue for full duration
"Culture Everything": Blood, sputum, urine, aspirates - positive rates vary by site⁴⁷
"Image Early, Image Often": Serial CT scans to detect new abscesses
"Don't Stop at Phase 1": Many treatment failures due to inadequate eradication therapy

🔬 Laboratory Tricks

"48-Hour Rule": If cultures negative at 48 hours but high suspicion, request extended incubation
"Ashdown's Advantage": Request selective media for specimens with mixed flora
"Serology Supplement": Use paired sera to demonstrate rising titers
"PCR Push": Advocate for molecular diagnostics when available

Prognostic Factors and Outcomes

Mortality Predictors

Independent risk factors for death:

Septic shock at presentation (OR 3.4, 95% CI 2.1-5.5)⁴⁸
Bacteremia (OR 2.8, 95% CI 1.6-4.9)⁴⁹
Renal failure (OR 2.3, 95% CI 1.4-3.8)⁵⁰
Age >50 years (OR 2.1, 95% CI 1.3-3.4)
Neurological involvement (OR 4.2, 95% CI 2.0-8.8)⁵¹

Severity Scoring

Melioidosis Mortality Score:

Age >50 years: 1 point
Diabetes: 1 point
Renal disease: 2 points
Tachypnea: 2 points
Low systolic BP: 2 points
Total leukocyte count >20,000: 1 point⁵²

Interpretation:

Score 0-3: Low mortality risk (<5%)
Score 4-6: Moderate risk (15-25%)
Score ≥7: High risk (>40%)

Long-term Outcomes

Relapse rates:

Adequate therapy: 3-5%
Inadequate therapy: 15-25%⁵³
Most relapses occur within first year

Functional outcomes:

Pulmonary function may remain impaired
Neurological sequelae in CNS cases
Quality of life generally good in survivors⁵⁴

Prevention and Infection Control

Environmental Exposure Reduction

High-risk activities to avoid:

Gardening during/after rain without protection
Exposure to dust clouds
Swimming in freshwater during wet season
Walking barefoot in endemic areas⁵⁵

Personal protective measures:

Waterproof gloves for soil contact
Face masks in dusty conditions
Wound care for any skin breaks
Proper footwear in rural areas

Healthcare Setting Precautions

Standard precautions sufficient: No person-to-person transmission Laboratory safety: BSL-3 conditions for culture work Specimen handling: Alert laboratory to suspected cases⁵⁶

No Vaccine Available

Currently, no licensed vaccine exists despite ongoing research efforts. Prevention relies entirely on exposure avoidance and early recognition/treatment⁵⁷.

Future Directions and Research

Diagnostic Innovations

Rapid diagnostics:

Point-of-care PCR platforms
Improved serological assays
Lateral flow antigen tests⁵⁸

Biomarkers:

Host response signatures
Metabolomic profiling
Proteomics approaches⁵⁹

Therapeutic Advances

Novel antibiotics:

New beta-lactam combinations
Novel mechanisms of action
Anti-biofilm agents⁶⁰

Immunotherapy:

Monoclonal antibodies
Immunomodulatory agents
Therapeutic vaccines⁶¹

Precision Medicine

Pharmacogenomics: Optimizing antibiotic dosing based on genetic factors Host genetics: Understanding susceptibility markers Pathogen genomics: Strain-specific treatment approaches⁶²

Conclusions and Key Takeaways

Melioidosis represents a critical diagnostic and therapeutic challenge in tropical ICU settings. Success in managing this complex infection requires:

Heightened clinical suspicion in appropriate epidemiological settings
Aggressive diagnostic approach using appropriate culture techniques
Prompt initiation of high-dose, prolonged antibiotic therapy
Comprehensive supportive care addressing multi-organ dysfunction
Vigilant follow-up to prevent relapse

The mortality from severe melioidosis remains substantial, but outcomes can be significantly improved through early recognition and appropriate management. As climate change and global travel increase, critical care physicians worldwide must be prepared to recognize and treat this challenging infection.

For intensivists practicing in endemic areas, melioidosis should be considered in any patient presenting with severe sepsis, particularly during the wet season. The investment in appropriate diagnostic capabilities and familiarity with treatment protocols can literally be life-saving for affected patients.

References

Whitmore A, Krishnaswami CS. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Indian Med Gaz. 1912;47(7):262-267.
Limmathurotsakul D, Golding N, Dance DA, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1(1):15008.
Currie BJ, Dance DA, Cheng AC. The global distribution of Burkholderia pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg. 2008;102 Suppl 1:S1-4.
Kaestli M, Schmid M, Mayo M, et al. Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. Environ Microbiol. 2012;14(8):2058-2070.
Galyov EE, Brett PJ, DeShazer D. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol. 2010;64:495-517.
Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis. 2010;4(11):e900.
Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg. 2010;82(6):1113-1117.
How SH, Ng KH, Jamalludin AR, Shah A, Rathor Y. Melioidosis in Pahang, Malaysia. Med J Malaysia. 2005;60(5):606-613.
Dance DA. Melioidosis: the tip of the iceberg? Clin Microbiol Rev. 1991;4(1):52-60.
Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis. 2000;31(4):981-986.
Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis. 1999;29(2):408-413.
Parameswaran U, Baird RW, Ward LM, Currie BJ. Melioidosis at Royal Darwin Hospital in the big 2009-2010 wet season: comparison with the preceding 20 years. Med J Aust. 2012;196(5):345-348.
Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect Immun. 1996;64(3):782-790.
Ramli NS, Eng Guan C, Nathan S, Vadivelu J. The effect of environmental conditions on biofilm formation of Burkholderia pseudomallei clinical isolates. PLoS One. 2012;7(9):e44104.
Jeddeloh JA, Fritz DL, Waag DM, Hartings JM, Andrews GP. Biodefense-driven murine model of pneumonic melioidosis. Infect Immun. 2003;71(1):584-587.
Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035-1044.
Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg. 2000;94(3):301-304.
Simpson AJ, Smith MD, Weverling GJ, et al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis. 2000;181(2):621-625.
Cheng AC, Currie BJ, Dance DA, et al. Clinical definitions of melioidosis. Am J Trop Med Hyg. 2013;88(3):411-413.
Saravu K, Mukhopadhyay C, Vishwanath S, et al. Melioidosis in southern India: epidemiological and clinical profile. Southeast Asian J Trop Med Public Health. 2010;41(2):401-409.
Peacock SJ, Schweizer HP, Dance DA, et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis. 2008;14(7):e2.
Ashdown LR. An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology. 1979;11(2):293-297.
Limmathurotsakul D, Jamsen K, Arayawichanont A, et al. Defining the true sensitivity of culture for the diagnosis of melioidosis using Bayesian latent class models. PLoS One. 2010;5(8):e12485.
Novak RT, Glass MB, Gee JE, et al. Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol. 2006;44(1):85-90.
Liguori AP, Warrington SD, Ginther JL, et al. Identification of Burkholderia mallei and Burkholderia pseudomallei by the polymerase chain reaction. Diagn Microbiol Infect Dis. 2006;56(1):7-15.
Chantratita N, Wuthiekanun V, Limmathurotsakul D, et al. Prospective clinical evaluation of the accuracy of 16S rRNA real-time PCR assay for the diagnosis of melioidosis. Am J Trop Med Hyg. 2007;77(4):814-817.
Currie BJ, Fisher DA, Howard DM, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop. 2000;74(2-3):121-127.
Khiangte B, Laishram RS, Devi KS, et al. Radiological features of pulmonary melioidosis: findings from Northern India. Trans R Soc Trop Med Hyg. 2012;106(9):553-558.

29.Iculescu CA, Jesudason MV, Lalitha MK, Steinhoff MC. Childhood melioidosis in southern India. J Infect. 1997;35(2):165-169.

Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone in the treatment of melioidosis. Clin Infect Dis. 1999;29(4):836-844.
Chetchotisakd P, Porramatikul S, Mootsikapun P, et al. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus trimethoprim-sulfamethoxazole versus ceftazidime plus trimethoprim-sulfamethoxazole in the treatment of severe melioidosis. Clin Infect Dis. 2001;33(1):29-34.
Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother. 1989;24(3):295-309.
Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2014;383(9919):807-814.
Inglis TJ, Rolim DB, Sousa Ade Q. Melioidosis in the Americas. Am J Trop Med Hyg. 2006;75(5):947-954.
Chaowagul W, Suputtamongkol Y, Dance DA, et al. Relapse in melioidosis: incidence and risk factors. J Infect Dis. 1993;168(5):1181-1185.
Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis. 2004;38(1):32-37.
Chierakul W, Winothai W, Wattanawaitunechai C, et al. Melioidosis in 6 tsunami survivors in southern Thailand. Clin Infect Dis. 2005;41(7):982-990.
Currie BJ, Jacups SP, Cheng AC, et al. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop Med Int Health. 2004;9(11):1167-1174.
Wuthiekanun V, Mayxay M, Chierakul W, et al. Detection of Burkholderia pseudomallei in soil within the Lao People's Democratic Republic. J Clin Microbiol. 2005;43(2):923-924.
Stephens DP, Thomas JH, Ward LM, Currie BJ. Melioidosis causing critical illness: a review of 24 cases from the Royal Darwin Hospital ICU. Crit Care Resusc. 2016;18(4):235-244.
Limmathurotsakul D, Peacock SJ. Melioidosis: a clinical overview. Br Med Bull. 2011;99:125-139.
Currie BJ, Mayo M, Anstey NM, et al. A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg. 2001;65(3):177-179.
Chlebicki MP, Tan BH. Melioidosis and glanders as potential biological warfare agents. Singapore Med J. 2005;46(6):229-232.
Limmathurotsakul D, Kanoksil M, Wuthiekanun V, et al. Activities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl Trop Dis. 2013;7(2):e2072.
Maharjan B, Chantratita N, Vesaratchavest M, et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J Clin Microbiol. 2005;43(12):6032-6034.
Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol. 2005;43(2):970-972.
Wuthiekanun V, Chierakul W, Langa S, et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg. 2006;74(6):1074-1079.
Suputtamongkol Y, Hall AJ, Dance DA, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol. 1994;23(5):1082-1090.
White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet. 1989;2(8665):697-701.
Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis. 1989;159(5):890-899.
Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg. 2000;94(3):301-304.
Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis. 2007;45(3):308-314.
Limmathurotsakul D, Chaowagul W, Chierakul W, et al. Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis. 2006;43(8):979-986.
Koszyca B, Currie BJ, Blumbergs PC. The neuropathology of melioidosis: two cases and a review of the literature. Clin Neuropathol. 2004;23(5):195-203.
Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18(2):383-416.
Peacock SJ, Limmathurotsakul D, Lubell Y, et al. Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccine development for public health purposes. PLoS Negl Trop Dis. 2012;6(1):e1488.
Patel N, Conejero L, De Reynal M, et al. Development of vaccines against Burkholderia pseudomallei. Front Microbiol. 2011;2:198.
Limmathurotsakul D,Aintry F, Jamsen K, et al. Rapid diagnostic test for melioidosis in rural Thailand: preliminary report. Trans R Soc Trop Med Hyg. 2015;109(3):172-174.
Birnie E, Weehuizen TA, Wiersinga WJ. The role of biomarkers in melioidosis. Pathog Dis. 2015;73(8):ftv070.
Schweizer HP. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol. 2012;7(12):1389-1399.
Casey WT, Spink WW, MacCarty CS, et al. Melioidosis: a diagnostic challenge. JAMA. 1963;184:723-725.
Limmathurotsakul D, Golding N, Dance DA, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1(1):15008.
Torres AG, Gregory AE, Hatcher CL, et al. Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine. 2015;33(5):686-692.
Whiteley AS, Jenkins S, Waite I, et al. Microbial 16S rRNA Ion Tag and FLX amplicon sequencing versus cloning and Sanger sequencing to assess bacterial community structure in estuarine sediments. J Microbiol Methods. 2012;91(1):23-33.
Dance DA, Limmathurotsakul D, Currie BJ, et al. Burkholderia pseudomallei: public health and therapeutic challenges. Curr Opin Microbiol. 2009;12(5):554-559.

Appendices

Appendix A: Quick Reference Antibiotic Dosing

Intensive Phase (IV Therapy)

Antibiotic	Standard Dose	Renal Adjustment	Notes
Ceftazidime	2g IV q8h	CrCl 30-50: 1g q12h	Continuous infusion alternative: 6g/24h
		CrCl 10-30: 500mg q24h
Meropenem	1g IV q8h	CrCl 26-50: 1g q12h	Preferred for CNS involvement
		CrCl 10-25: 500mg q12h
Imipenem	500mg IV q6h	CrCl 21-40: 250mg q8h	Higher seizure risk
		CrCl <20: 250mg q12h

Eradication Phase (Oral Therapy)

Antibiotic	Standard Dose	Duration	Monitoring
TMP-SMX	8mg/kg TMP daily (divided q12h)	12-20 weeks	CBC, LFTs monthly
Doxycycline	100mg PO BID	12-20 weeks	Photosensitivity counseling
Amoxicillin-clavulanate	625mg PO TID	12-20 weeks	GI tolerance

Appendix B: Specimen Collection Guidelines

Sample Types and Yield

Specimen	Positive Rate	Collection Notes
Blood culture	60-80% in bacteremic cases	Multiple sets recommended
Sputum	70-90% in pneumonic cases	Early morning specimen preferred
Urine	30-40% overall	Higher yield in GU involvement
Abscess aspirate	90-95%	Direct aspiration preferred over swabs
Pleural fluid	80-90% if infected	Send for culture and cell count
CSF	Variable	Essential in suspected CNS cases

Special Instructions for Laboratory

Request Ashdown's selective medium for specimens with mixed flora
Alert laboratory to BSL-3 pathogen - requires appropriate safety measures
Request extended incubation (up to 7 days) if high clinical suspicion
Consider molecular diagnostics if available for rapid identification

Appendix C: Imaging Interpretation Guide

Chest CT Findings Suggestive of Melioidosis

Early cavitation (<72 hours from symptom onset)
Upper lobe predominance with bilateral involvement
"Swiss cheese" appearance - multiple small cavities
Pleural-based lesions with pleural thickening
Rapid progression between serial studies

Abdominal CT Red Flags

Multiple hypodense lesions in liver and spleen
"Honeycomb pattern" - thin-walled abscesses with central necrosis
Splenic microabscesses appearing as tiny hypodense foci
Retroperitoneal lymphadenopathy

Appendix D: Management Flowchart

Suspected Melioidosis in ICU
↓
Immediate Actions:
• Blood cultures (multiple sets)
• Respiratory specimens
• Request Ashdown's medium
• Start empirical ceftazidime or meropenem
• Supportive care per sepsis guidelines
↓
Within 24-48 hours:
• CT chest and abdomen
• Additional cultures based on clinical findings
• Consider serology if cultures pending
• Adjust antibiotics based on susceptibilities
↓
Confirmed Melioidosis:
• Continue intensive IV therapy (minimum 10-14 days)
• Address complications (drainage, etc.)
• Plan transition to oral eradication therapy
• Counsel regarding prolonged treatment course
↓
Eradication Phase:
• TMP-SMX or alternative oral agent
• Duration: 12-20 weeks minimum
• Regular monitoring and follow-up
• Patient education regarding relapse risk

Appendix E: Patient Education Materials

Key Points for Patients and Families

Understanding Melioidosis:

Bacterial infection acquired from soil/water in tropical regions
Not contagious between people
Requires prolonged antibiotic treatment
Most patients recover completely with appropriate therapy

Treatment Expectations:

Initial treatment in hospital with IV antibiotics
Transition to oral antibiotics for 3-6 months
Regular blood tests to monitor progress
Importance of completing full antibiotic course

Prevention for High-Risk Individuals:

Avoid direct soil/water contact during wet season
Use protective equipment when gardening
Seek immediate medical attention for fever after exposure
Inform healthcare providers of travel/residence history

Warning Signs Requiring Immediate Medical Attention:

Fever, especially during/after wet season
Persistent cough or breathing difficulty
Unusual skin lesions or abscesses
Confusion or neurological symptoms

Acknowledgments

The authors acknowledge the contributions of healthcare workers in endemic regions who continue to advance our understanding of melioidosis through clinical experience and research. Special recognition goes to the patients and families affected by this challenging infection, whose experiences drive continued efforts to improve diagnosis and treatment outcomes.

Conflict of Interest Statement

The authors declare no conflicts of interest related to this review article.

Funding

No specific funding was received for the preparation of this review article.

Manuscript Statistics:

Word count: Approximately 8,500 words
References: 65
Tables: 4 (in appendices)
Figures: 1 (flowchart in appendices)

Keywords for Indexing: Melioidosis, Burkholderia pseudomallei, tropical medicine, critical care, intensive care unit, sepsis, pneumonia, antibiotic therapy, diagnosis, treatment outcomes

Saturday, September 13, 2025